Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Oxfordshire Local Enterprise Partnership (OxLEP) has secured funding to support the University of Oxford’s Clinical BioManufacturing Facility (CBF) – a UK leader in the production of vaccines for early phase clinical trials, including the Oxford-AstraZeneca vaccine.

Professor Catherine Green © John Cairns

The enabling works will see the refurbishment of the Clinical BioManufacturing Facility’s cleanroom and storage facilities, as well as enabling works in support of future expansion.

The further expansion will include the creation of additional clean rooms, providing space to deliver up to 10 clinical grade products (gene therapies, vaccines, biologics) to trial per year. This creates the potential to increase the UK's share of the global vaccine and biologics manufacturing market worth over £735 million.

The funding comes as part of the government’s Getting Building Fund, which aims to help kick-start the UK economy following the emergence of the COVID-19.

OxLEP – working with the University of Oxford – secured £200,000 of funding for CBF through the fund, with the total cost of the project being £250,000.

Read the full story on the University of Oxford website